Used in pharmaceutical research as a targeted protein degrader, particularly in the development of proteolysis-targeting chimeras (PROTACs). Its structure enables selective binding to specific disease-related proteins, facilitating their degradation via the cell’s ubiquitin-proteasome system. This makes it valuable in oncology and inflammatory disease research, where modulating protein levels is critical. The compound's polyether chain enhances solubility and cellular permeability, improving bioavailability in cellular assays. Its cyanocyclopropane and thiazole components contribute to binding affinity and metabolic stability, supporting use in preclinical studies for optimizing degrader therapeutics.